Patients with endogenous or exogenous glucocorticoid (GC) excess exhibit a range of side
effects, including an increased risk of infections. Via both mechanism, immune impairments …

The pandemic of coronavirus disease (COVID-19), a disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is causing high and rapid morbidity and …

Abstract Purpose Glucocorticoids (GCs), alone or associated to other drugs, were widely
used in the management of patients affected by severe acute respiratory syndrome caused …

Abstract Purpose Coronavirus disease-19 (COVID-19) has spread throughout the world. It
was initially defined as a potentially severe syndrome affecting the respiratory tract, but it has …

Coronavirus disease 2019 (COVID-19) is a highly heterogeneous disease regarding
severity, vulnerability to infection due to comorbidities, and treatment approaches. The …

Abstract Objective Since January 2020, the highly contagious novel coronavirus SARS-CoV-
2 has caused a global pandemic. Severe COVID-19 leads to a massive release of …

The coronavirus disease 2019 (COVID-19) is an emerging pandemic challenge. Acute
respiratory distress syndrome (ARDS) in COVID-19 is characterized by a severe cytokine …

Introduction: Currently, only glucocorticoids have proved to impact adverse outcomes in
COVID-19. However, their risk/benefit balance remains inconclusive and populations' …

In critically ill patients affected by severe acute respiratory syndrome caused by Sars-Cov-2
infection, steroids, usually methylprednisolone, are currently administered despite data on …

In November 2019, the Italian Society of Endocrinology (SIE) has published a consensus
statement on the tailoring of glucocorticoid replacement in adrenal insufficiency [1]. A few …